Format

Send to

Choose Destination
Curr Opin Mol Ther. 2006 Oct;8(5):461-7.

Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.

Author information

1
Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au

Abstract

ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase 11 clinical trials, while phase I trials are underway with an oral formulation of the drug.

PMID:
17078389
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center